
If Butterfly Network sat on your watchlist instead of in your portfolio, the return may sting. Holding Butterfly Network over the past year would have returned 111.0%, including dividends. That kind of move invites a harder look at what was on record before it started, especially the assumption that AI driven software and broader ultrasound adoption could shift the business toward higher margin, recurring digital revenue. If you were weighing the stock back in November 2025, how clearly did that software transition thesis show up in the available information?
On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.
Butterfly Network is not the only name tied to this theme. Zero in on 33 healthcare AI stocks and compare how each one is priced.
The shares cost US$2.69 at the start of the period, and anyone circling Butterfly Network then was really choosing between two grounded but very different stories.
On the bullish side, the narrative set Fair Value at US$3.19, 19% above the start price. It leaned on expanding enterprise deals plus Compass AI and Butterfly Garden apps to support higher margin, recurring digital revenue tied to more accessible ultrasound diagnostics.
The bearish view put Fair Value at US$2 and stressed delays in closing large contracts, persistent cash burn, and the risk that high R&D spending and commoditization could delay or limit margin expansion.
The clearest update for Butterfly Network came from Q3 2026, when revenue was US$32.598m and the loss was US$12.807m. That result, alongside earlier quarters, leaned toward the bullish story of higher software and Embedded contribution, because revenue and profit both rose while net margin improved to a 39.3% loss, although profitability remained unproven.
The lesson is simple. When a thesis hinges on a software shift, track the mix. Look at segment disclosures, gross margin and recurring licensing or subscription lines to see if the higher margin engine is actually scaling.
Butterfly Network now trades at US$6.14, so the cautious Narrative sees its Fair Value below that level. The argument highlights ultrasound on a chip, Compass AI and licensing deals as the real economic engine rather than just device sales.
A buyer today effectively banks on sustained commercial traction without heavy dilution. The question is how that confidence lines up with the Narrative's concern about possible future share issuance.
"The only reason that I didn't buy thousands of shares is the fact that many upstart companies dilute existing investor shares by offering more shares to the public to raise money. But there is a silver lining to this: it will most likely not happen here because this company has a strong balance sheet with no debt to equity and a 3 year cash runway, which would be long enough time for this company to be in profit land with no need to offer more shares."
One Narrative disagrees with today's price. → See where this Narrative says Butterfly Network should trade
By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.
Those are three of them. See every one of the 34 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com